Shows / The Top Line

The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
The show, from its episodes
No episode notes yet. Recurring topics, people and starter picks will appear when notes are available.
Typical episode length
19m · median of 129 episodes with a known length
Solo / guest format
Unknown — existing notes name people mentioned, but do not identify hosts or guests.
Recurring topics
No recurring topics established yet.
Recurring people
No recurring people established yet.
Start here
No starter picks yet — no published episodes with audio and a recorded notes hook.
Episodes
The Top LineAngela Hwang on her pivot from Big Pharma to biotech
Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies. In this…
The Top LineElevAAte and the push for East Asian American leaders in biopharma
Although East Asians make up a significant share of entry-level roles in U.S. biopharma, few have risen to senior leadership positions. That disparity is what…
The Top LineAngus on Angus: A Fierce oncology discussion
We’ve known for a while that there are two Anguses—both journalists covering oncology at health- and biopharma-focused news outlets. Now, for the…
The Top LineNavigating Trump’s tariffs for pharma
After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits…
The Top LineQ1 biopharma layoff trends, plus expectations for Q2
In this week’s episode of "The Top Line," Fierce Deputy Editor Andrea Park and Fierce Biotech Senior Editor Gabrielle Masson discuss how workforce…
The Top LineA closer look at pharma's top R&D budgets
In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from…
The Top LineWhat diversity means in medtech
Since the first days of the new Trump administration, the White House has handed down orders to ban work focused on diversity, equity and inclusion (DEI)…
The Top Line5 Key Questions About Precision Patient Marketing—Answered (Sponsored)
In this episode of The Top Line, sponsored by PatientPoint, Andrew Schultz, President of PatientPoint Precision, discusses how hypertargeting and contextual…
The Top LineA closer look at pharma’s top patent losses in 2025
Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics…